Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (358)	11/29/1999 12:03:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 455

Medical Newsletter's McCamant Likes 2nd-Tier Biotechs NEW YORK -- Jim McCamant of the Medical Technology Newsletter believes that the recent momentum in biotechnology stocks poses a good investment opportunity in the second-tier companies within the sector. In a CNBC interview Monday, McCamant said he prefers to dig a little deeper to find value in companies that haven't traditionally led the sector. McCamant likes Isis Pharmaceuticals Inc. (ISIP) because of the products in its pipeline and because the stock is undervalued. He also recommends Ligand Pharmaceuticals Inc. (LGND), which he predicts will turn profitable next year. McCamant's other stock picks include Axys Pharmaceuticals Inc. (AXPH) and ImClone Systems Inc. (IMCL). -Zahida Hafeez; Dow Jones Newswires; 201-938-5176